🟢 Opus Genetics is trading 8.8% up in pre-market today after positive interim BIRD-1 data

Opus Genetics is trading 8.8% up in pre-market today at $4.72 after reporting positive interim Phase 1/2 BIRD-1 data for OPGx-BEST1.

• All five participants in the low-dose cohort reportedly showed clinically meaningful vision improvement with a favorable safety profile.
• The company had scheduled its Cohort 1 topline-data webcast for 8:00 a.m. ET on September 9, 2026.